Post on 23-May-2020
DIAD Family Webinar 26 Oct 2019 2
DIAD Family WebinarSaturday, October 26, 20194:00-6:00 PM CDT / 22:00 – 00:00 BST
RANDALL BATEMAN, M.D. DIREC TOR, D IAN TRIALS UNIT
ERIC MCDADE. D.O. ASSOCIATE DIREC TOR, D IAN TRIALS UNIT
AGENDABreaking news on aducanumabOpen Label Extension (OLE)Cognitive Run-In (CRI) Next Steps: Future Drug ArmsPrimary Prevention UpdateDIAN Expanded Registry (EXR) and Family Conference
recap
If you have a question during the webinar, please use the chat function and type in your question or email it to: dianexr@wustl.edu
DIAD Family Webinar 26 Oct 2019 3
EMERGE/ENGAGE OverviewTwo identically designed Phase 3 studies
Enrolled patients with mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia
All patients screened with PET for elevated brain amyloid beta levels
~ 2/3 of patients were ApoE4 carriers in each study, well balanced across arms
Primary endpoint: CDR-SB (Clinical Dementia Rating-Sum of Boxes) at 18 months
All treatment arms included titration
DIAD Family Webinar 26 Oct 2019 4
DIAD Family Webinar 26 Oct 2019 5
Summary of Phase 3 aducanumab dataAcross multiple clinical endpoints, the larger aducanumab dataset demonstrated a statistically significant reduction of clinical decline in early AD patients in EMERGE, and Biogen believes data from a subset of ENGAGE support these findings
Exposure to high dose aducanumab was important for efficacy
Differences in exposure to high dose aducanumab largely explain the different results between the futility analysis and the new analysis of this larger dataset, as well as the different results between the two studies
Following consultation with the FDA, Biogen believes it is reasonable to submit a regulatory filing for aducanumab based on these data
DIAD Family Webinar 26 Oct 2019 6
Open Label Extension (OLE) An Open Label Extension (OLE) study is a period in a study following the
double-blind period where all participants get active study drug and it is not blinded (everyone is aware of active treatment administration) This permits participants to receive active drug while regulatory agencies review
drug applications for approval; this bridges the timeframe to a marketing approval to get drug from your doctor.
This allows continued assessment of the efficacy, durability, and sustainability of the treatment.
Further, it enables additional data collection and information of the treatment by assessing participants who received placebo in the double-blind and then receive active in the OLE period (this is known as ‘cross-over’)
All participants: Must still be active in the study and cannot have met any discontinuation criteria
required by the protocol Will start OLE as though it’s their first dose, i.e. re-start titration however the MRI
schedules may be less than before due to availability of more safety data
DIAD Family Webinar 26 Oct 2019 7
Open Label Extension (OLE) If the drug arm you are in is not positive but the other drug arm is, you will be
allowed to switch; however, a period of at least 6 months must have passed since your last dose of the other drug (6 month ‘washout’ period)
Timing: It is possible that OLE may start in March/April/May 2020
Participants WILL have to know their mutation status for OLE!
Will I learn whether I was on active or placebo in the double-blind period? To maintain the integrity of the data and assessment (including cross-over) in the OLE
period, participants will NOT be informed of whether they were on active or placebo. This will alleviate any unintentional bias by sites or participants for the clinical and
cognitive measures. It may be possible to find out whether you were on active or placebo once the OLE period
has ended. This information would not change your medical or trial management
DIAD Family Webinar 26 Oct 2019 8
OLE Genetic Counseling & Testing - Discussion The OLE period does not include a placebo, so you must
know you are a mutation carrier in order to enroll into OLE.
Polling questionsPlease contact the DIAN EXR at dianexr@wustl.edu or call 844-DIAN-EXR (844-342-6397) to arrange genetic counseling and testing.
It may be possible to use results of genetic testing done through the trial (to clinical standards). The EXR will discuss options with you.
DIAD Family Webinar 26 Oct 2019 9
OLE Procedures Annual Visits: Lumbar puncture PET Scan: PIB-PET and AV-1451 tau PET MRI Blood biomarkers
Additional Requirements - Solanezumab: no ECG, no safety labs, 1 titration safety MRI
Additional Requirements - Gantenerumab: Local Baseline ECG (if one not performed in the prior 6 months) Annual safety labs New formulation for OLE = G4 (more bioavailable / less volume) Decreased MRI frequency (but still included in titration ~ every 3 dose)
DIAD Family Webinar 26 Oct 2019 10
Enrollment into CRI is active when a drug arm is not open for recruitment. Primary Prevention: ≤ -15 estimated years to onset or “EYO” (younger /
earlier than -15 years from age of onset) Secondary Prevention: -15 to +10 EYO
Purpose / Benefit of CRI: This is part of next drug arm! Provides statistical power for future drug arm(s): participant data will be
used in primary endpoint analysis of treatment arm once added Pre-identified group of participants (more rapid enrollment once drug arms
open) Reduce recruitment time once open allows for earlier readout (and rapid
drug availability to population, if positive) Decreased regulatory start-up (initial/new submission vs. amended
submission timeline)
DIAD Family Webinar 26 Oct 2019 11
Cognitive Run-In (CRI)
Cognitive Run-In (CRI)Participation includesHome screening visit Initial, baseline visit to study site (to increase probability of
meeting inclusion when drug arm is added) Clinical and cognitive testing batteryMRI scan Possible tau PET scan (secondary prevention only, i.e. -15 to +10 EYO)
In-home, abbreviated cognitive testing visits approximately every 3 months, with a longer home version at 6 monthsAnnual visits to study site
12DIAD Family Webinar 26 Oct 2019
Next Steps: Future Drug ArmsFor Primary Prevention
1) Several classes of compounds are being considered for the next drug arm2) BACEi with reported cognitive worsening, pending updates for ongoing
programs
For Secondary Prevention1) Tau based drugs including antibodies are high priority for secondary
prevention Tau PET scans needed to help power future studies
2) Combination therapy with anti-amyloid-beta antibodies with tau targeted drug high priority and possible with OLE success of first amyloid drugs
DIAD Family Webinar 26 Oct 2019 13
CRI – Tau NexGen NIH grant was submitted October 7th for 2 of the 3 tau
NexGen drugs (1st tau drug has already been funded)
If site is approved for CRI and enrolls, those participants will most likely be randomized to drug first (from a logistical standpoint).
The randomization for DIAN-TU Tau NexGen is planned for late 2020, with one or two tau based drugs (depending on NIH funding for second drug, and contracting/roll-out).
Each drug arm enrollment may be 100.
We expect to have ~100 CRI enrolled by later 2020.
DIAD Family Webinar 26 Oct 2019 14
DIAN-TU Tau NexGen trials: Planned enrollment by arms
DIAD Family Webinar 26 Oct 2019 15
Three classes of tau agents1. Anti-tau monoclonal antibodies
2. Genetic treatments designed to inhibit or modulate tau protein translation (e.g. antisense oligonucleotides [ASOs], small interfering RNA [siRNA], and adeno-associated viral [AAV] vectors)
3. Small molecule aggregation inhibitors. We propose to test each of these different mechanistic classes in the DIAN-TU
DIAD Family Webinar 26 Oct 2019 16
Primary Prevention Plan: Update Officially funded in Sept 2018 (initial five years)
EYO -15 or earlier (younger)
Amyloid-specific therapies for a PiB outcome
4 years treatment (until last participant completes 4 years)
Therapy evaluation assessments: Plan for Q4 2019-Q1 2020 for drug selection Possible drug classes: Abeta Vaccines, Passive immunotherapy (Abeta) Results of 001 could impact the decisions for 002 (timelines)
For those of you that might qualify, please consider enrolling in the CRI.
DIAD Family Webinar 26 Oct 2019 17
DIAN Expanded Registry (DIAN EXR) Provides information on current and future research opportunities focused on
dominantly inherited AD (DIAD)
Primary referral source for the DIAN-TU Trial
Two-way communication mechanism: Rapid outreach to families; vehicle for families to contact with questions
Additional benefits:◦ Source of information on dominantly inherited AD◦ Quarterly DIAN EXR newsletter◦ DIAD Family Conferences◦ Archived webinars◦ EXR ARC◦ Surveys to formally collect information from registrants on topics important to DIAN and to
DIAN-TU trial design◦ Exploratory Genetic Counseling and Testing (GCT) Program◦ Genetic counseling and testing for qualified family members interested in DIAN research but
who have not yet enrolled in DIAN-TU trial or DIAN Observational study
DIAD Family Webinar 26 Oct 2019 18
DIAN Expanded Registry (DIAN EXR)
Serves as a key information and referral source for the DIAN Observational and DIAN-TU trials
Register: www.dianexr.orgCall: 1-844-DIAN-EXR (342-6397)
Email: dianexr@wustl.edu
Participant Interaction and Partnership
19DIAD Family Webinar 26 Oct 2019
2019 DIAD Family Conference: Mutation, Participation, Innovation
DIAD Family Webinar 26 Oct 2019 20
Total attendees: 245• 131 family members and 114 researchers/professionals from
14 countries (United States and Puerto Rico, Argentina, Australia, Brazil, Canada, Colombia, Germany, Greece, Japan, Mexico, The Netherlands, Spain and the UK)
• Video recording of presentations now available on the DIAN website at: https://dian.wustl.edu/for-families/family-conferences/2019
Saturday, July 13thJ.W. Marriott LIVE • Los Angeles, CA USA
DIAD Family Webinar 26 Oct 2019 21
Coming Soon: DIAN Participant Portal Presenting the Linkt app! A single
location for DIAN-related activity
Receive study opportunities, reminders, news, and announcements
Colorful, game-like setting with goals and rewards
Interaction with the ARC smartphone app
Also available via desktop/laptop
Invites to go out to Expanded Registry via email within the next month! Aiming for Obs involvement to follow
Through public/private support and partnership, the DIAN-TU has launched trials to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer’s disease drug developments.
U01 AG042791, R01 AG046179,R01/R56 AG053267, R13 AG055232,U01 AG059798
*Financial support has also been provided by anonymous sources.
DIAN-TU Pharma Consortium
DIAD Family Webinar 26 Oct 2019 22
DIAN-TU Administrative and Clinical Operations TeamRandall Bateman – Director and PI, Eric McDade – Associate Director
Sarah Adams, Stephanie Belyew, Erin Cattoor, David Clifford, Garland Edmonds, Molly Fitzgerald, Erica Fowler, Amanda Fulbright, Angela Fuqua, Kurtis Hanks, Ron Hawley, Dottie Heller, Latoya Jones, Michelle Jorke, Nicole Kelley,
Paulette MacDougall, Jacki Mallmann, Tayona Mayhew, Karen McCann, Susan Mills, Julie Murphy, Jennifer Petranek, Anna Santacruz, Jeanette Schillizzi, Jessi Smith, Annette Stiebel, Shannon Sweeney, Linda Watkins-Imhof, Ellen Ziegemeier
DIAN-TU CoresProject Arm Leaders: Steve Salloway, Martin Farlow, Lon SchneiderConsultants : Berry Consultants, Cornelia Kamp, Cardinal Health Regulatory Sciences, Granzer Regulatory Consulting, IQVIADIAN-TU Therapy Evaluation Committee: Paul Aisen, Randall Bateman, Jasmeer Chhatwal, Dave Clifford, David Cribbs, Kelly Dineen, Joel Eissenberg, Heidi Gibbar, David Holtzman, Mathias Jucker, Jeffrey Kelly, Virginia Lee, Cynthia Lemere, Eric McDade, Erik Musiek, Erik Roberson, Matthias Staufenbiel, Robert VassarDSMB Members: Gary Cutter, Steve Greenberg, Scott Kim, David Knopman, Kristine YaffeADCS: Ron Thomas ATRI: Paul AisenUniversity of Michigan: Robert KoeppeMayo Clinic: Clifford Jack
Administrative: Randall Bateman, Eric McDade and teamBiomarkers: Anne Fagan and teamBiostatistics: Chengjie Xiong, Guoqiao Wang and teamCognition: Jason Hassenstab and teamGenetics: Alison Goate, Carlos Cruchaga and teamImaging: Tammie Benzinger and teamNeuropathology: Rick Perrin and team
We gratefully acknowledge the DIAN and DIAN-TU participants and family members, DIAN Team, DIAN Steering Committee, Knight ADRC, Alzheimer’s Association, ADAD Forum, NIH U01AG042791, R01AG046179, R01/R56AG053267, U01AG059798, R13AG055232, DIAN-TU Pharma Consortium, GHR, Anonymous Foundation, Industry Partners (Eli Lilly & Co., Hoffman-LaRoche, Janssen, Avid Radiopharmaceuticals, Bracket, Cogstate), and Regulatory Representatives.
DIAN-TU Collaborators
Page 23DIAD Family Webinar 26 Oct 2019
DIAN-TU Sites
United StatesUniversity of Alabama, Birmingham, Erik RobersonUSC Keck School of Medicine, Sonia Pawluczyk*University of California, San Diego, Doug GalaskoYale University, Christopher van DyckAdvocate Lutheran General Hospital, Darren GitelmanIndiana University, Jared BroschEmory University, James LahWashington University, Joy SniderColumbia University, Lawrence HonigUniversity of Pittsburgh, Sarah BermanUniversity of Puerto Rico, Ivonne Jimenez-VelazquezButler Hospital/Brown University, Ghulam SurtiUniversity of Texas Southwestern Medical Center, Diana KerwinUniversity of Washington, Seattle, Suman Jayadev
FranceHôpital Roger Salengro, Florence PasquierHôpital Neurologique Pierre Wertheimer, Maité FormaglioGroupe Hospitalier Pitie-Salpetriere, Bruno DuboisHôpital Charles Nicolle, David WallonHôpital Purpan, Jérémie Pariente
ItalyIRCCS Centro San Giovanni di Dio Fatebenefratelli, Giovanni FrisoniAzienda Ospedaliera Universitaria Careggi, Sandro Sorbi
CanadaUniversity of British Columbia, Robin HsiungSunnybrook Health Sci Centre, Mario MasellisMcGill University, Serge GauthierCHU de Quebec - Hôpital de l' Enfant Jésus, Robert Laforce*
United KingdomThe National Hospital for Neurology & Neurosurgery, Catherine Mummery
AustraliaMental Health Research Institute, Colin MastersMcCusker Foundation for AD Research, Roger ClarnetteNeuroscience Research Australia, William Brooks Spain
Hospital Clinic i Provincial de Barcelona, Raquel Sanchez-Valle
*New sites pending approval
24DIAD Family Webinar 26 Oct 2019
IrelandSt. Vincent’s University Hospital, Justin Kinsella
DIAD Family Webinar 26 Oct 2019 25
THANK YOU!!